Incanthera (AQSE:INC) Total Liabilities: £0.93 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Incanthera Total Liabilities?

Incanthera AQSE:INC -15.63% Total Liabilities is £0.93 Mil as of Sep. 2025. The stock has 2 warning signs investors should review.

Incanthera's Total Liabilities for the quarter that ended in Sep. 2025 was £0.93 Mil.

Incanthera's quarterly Total Liabilities increased from Sep. 2024 (£0.51 Mil) to Mar. 2025 (£0.55 Mil) and increased from Mar. 2025 (£0.55 Mil) to Sep. 2025 (£0.93 Mil).

Incanthera's annual Total Liabilities increased from Mar. 2023 (£0.41 Mil) to Mar. 2024 (£0.73 Mil) but then declined from Mar. 2024 (£0.73 Mil) to Mar. 2025 (£0.55 Mil).

Incanthera Total Liabilities Historical Data

* Premium members only.

The historical data trend for Incanthera's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incanthera Total Liabilities Chart

Incanthera Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Liabilities
Get a 7-Day Free Trial 0.17 0.20 0.41 0.73 0.55

Incanthera Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.73 0.51 0.55 0.93

Incanthera Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Incanthera's Total Liabilities for the fiscal year that ended in Mar. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.547+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.55

Total Liabilities=Total Assets (A: Mar. 2025 )-Total Equity (A: Mar. 2025 )
=1.7-1.153
=0.55

Incanthera's Total Liabilities for the quarter that ended in Sep. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.933+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.93

Total Liabilities=Total Assets (Q: Sep. 2025 )-Total Equity (Q: Sep. 2025 )
=1.689-0.756
=0.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of £0.93 Mil mean?
Incanthera (AQSE:INC) has a Total Liabilities of £0.93 Mil as of Sep. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Incanthera and its competitors.
Is Incanthera's Total Liabilities too high?
Incanthera's current Total Liabilities is £0.93 Mil.
How does Incanthera's Total Liabilities compare to VRTX and REGN?
Incanthera's Total Liabilities of £0.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Incanthera and its competitors. Incanthera's current Total Liabilities is £0.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incanthera stock overvalued right now?
Incanthera (AQSE:INC) has a current Total Liabilities of £0.93 Mil. The current Total Liabilities is £0.93 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Incanthera (AQSE:INC), the current Total Liabilities is £0.93 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Incanthera Business Description

Address C/o Gateley Plc, 98 King Street, Manchester, GBR, M2 4WU
Incanthera PLC is clinical stage drug development. It specializes in dermatology and oncology therapeutics. The company has launched a skincare range called Skin + CELL, which addresses and enhances life quality through effective delivery of bioactive ingredients capable of energising the skin's natural repair and defence processes at the cellular level. It has one reportable segment, namely the development of dermatology and pharmaceutical products, within the United Kingdom and Switzerland.